Optimal management of nasopharyngeal carcinoma
Authors:
- Sandrine FaivreSFSandrine Faivre
- François JanotFJFrançois Janot
- Jean-Pierre ArmandJAJean-Pierre Armand
- 1 May 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 16 (3) , 231-235
Abstract
Given the high rate of mortality still associated with advanced stages of nasopharyngeal carcinoma, this review focuses on some specific aspects of this potentially curable disease that could translate into improved therapeutic approaches. Epstein–Barr viral-induced carcinogenesis is almost constantly reported in the undifferentiated type of nasopharyngeal carcinoma. Nasopharyngeal carcinoma retains clonal characteristics and p53 functionality up to late stages that may account for its high level of chemo- and radiotherapy sensitivity, with several cases of long-term survivors reported among patients with bone metastasis. Recent imaging and biologic techniques will help to identify patients at risk of distant failures (detection of plasma Epstein–Barr virus DNA) or those harboring posttherapeutic residual diseases (positron emission tomographic scan). Cisplatin-based induction chemotherapy has shown disease-free survival benefit, whereas concomitant chemoradiotherapy is associated with an improved local–regional control. Late radiation-induced toxicities (especially xerostomia) will hopefully be reduced using intensity-modulated radiation therapy. New therapeutic agents such as taxanes, or targeted therapies (epidermal growth factor receptor inhibitors) are of major interest in the challenge of circumventing resistance to alkylating agents. Better knowledge of nasopharyngeal carcinoma pathogenesis and biology, management of patients in highly specialized oncologic units, and careful selection of cytotoxic agents along with multimodality integrated therapeutic programs will likely yield to improved survival, particularly for patients with locally advanced nasopharyngeal carcinoma.Keywords
This publication has 16 references indexed in Scilit:
- Timing of Chemoradiotherapy and Patient Selection for Locally Advanced Nasopharyngeal CarcinomaClinical Oncology, 2003
- Frequency of skeletal metastases in nasopharyngeal carcinoma after initiation of therapy: should bone scans be used for follow-up?Nuclear Medicine Communications, 2003
- Presence of the latent membrane protein 1 gene in nasopharyngeal swabs from patients with mucosal recurrent nasopharyngeal carcinomaCancer, 2003
- Nasopharyngeal carcinomasEuropean Journal of Cancer, 2003
- Epstein-barr virus latent membrane protein 1: Structure and functionsJournal of Biomedical Science, 2003
- 18‐Fluoro‐2‐deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imagingCancer, 2003
- Pretherapy quantitative measurement of circulating Epstein–Barr virus DNA is predictive of posttherapy distant failure in patients with early‐stage nasopharyngeal carcinoma of undifferentiated typeCancer, 2003
- Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal CarcinomaJNCI: Journal of the National Cancer Institute, 2002
- Staging computed tomography of the thorax for nasopharyngeal carcinomaHead & Neck, 2000
- Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal TypeJournal of Clinical Oncology, 2000